In relation to the trial cluster possibility, sure. But I heard we got stitched up by the investigator for the Melanoma trial (pushing another drug in front of QBiotics - which made recruitment almost impossible).
And people are totally cash strapped at the moment so dips in pre-revenue biotechs is par for the course...
@Alf107 summed it up nicely above, but perhaps a bit bullish. To get the that kind of market cap they need a commercial deal of some kind. So if those 5 things happen then we should be able to list at a reasonable price. Been a long time coming but just maybe the listing is on the horizon now.
